The novel GLP-1 receptor agonist ecnoglutide was associated with weight loss of 9.1% to 13.2% after 40 weeks in a Phase 3 trial with more than 600 participants with overweight or obesity, compared with 0.1% for those on placebo. The findings were presented at the American Diabetes Association’s 85th Scientific Sessions and published in The Lancet Diabetes & Endocrinology.
Full Story: Medscape (6/21)